Device Trial Radar · NCT06483945
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Feb 28, 2024
Primary completion
Mar 31, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- DexCom, Inc.Public (DXCM)
- Sponsor type
- Industry
- First posted
- Jul 3, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
Conditions
- Diabetes
Interventions
Dexcom CGM G6/G6 Pro/G7Device
Dexcom CGM G6/G6 Pro/G7 device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient Reported Outcomes (PROs)Time frame: 4 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Institute of Endocrinology Diabetes, Health & Hormones
Stockbridge, Georgia
Palm Research Center
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.